Lamivudine therapy in kidney allograft recipients who are seropositive for hepatitis B surface antigen

Filik L., Karakayali H., Moray G., Dalgic A., Emiroglu R., Ozdemir N., ...Daha Fazla

TRANSPLANTATION PROCEEDINGS, cilt.38, sa.2, ss.496-498, 2006 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 38 Sayı: 2
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1016/j.transproceed.2005.12.047
  • Dergi Adı: TRANSPLANTATION PROCEEDINGS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.496-498
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Background. There are numerous recent reports on the use of lamivudine for hepatitis B virus (HBV) infection after renal transplantation. However, the optimal strategy (prophylactic, preemptive, or salvage approach) for starting lamivudine treatment in this patient group has not been determined. The aim of this study was to assess how the timing of lamivudine therapy affected the HBV serological status and the transaminase levels in renal allograft recipients with chronic HBV infection.